诺比侃(02635)公布配发结果，公司全球发售378.66万股H股，香港公开发售占10%，国际发售占90%。 每股发售价80港元，全球发售净筹约2.57亿港元。每手50股H股，预期股份将于2025年12月23日上午九 时正(香港时间)开始在联交所买卖。 其中，香港公开发售获188.74倍认购，国际发售获2.08倍认购。 ...

其中，香港公开发售获188.74倍认购，国际发售获2.08倍认购。 智通财经APP讯，诺比侃(02635)公布配发结果，公司全球发售378.66万股H股，香港公开发售占10%， 国际发售占90%。每股发售价80港元，全球发售净筹约2.57亿港元。每手50股H股，预期股份将于2025 年12月23日上午九时正(香港时间)开始在联交所买卖。 ...

格隆汇12月22日丨壁仞科技(06082.HK)发布公告，公司拟全球发售约2.48亿股H股，中国香港发售股份 1238.48万股，国际发售股份约2.35亿股(以上可予重新分配及视乎发售量调整权及超额配股权行使与否 而定)；2025年12月22日至12月29日招股，预期定价日为12月30日；发售价将为每股发售股份17.00- 19.60港元，H股的每手买卖单位将为200股，中金公司、平安证券(香港)、及中银国际为联席保荐人； 预期股份将于2026年1月2日开始在联交所买卖。 ...

基石投资者方面，本次发行引入多家机构参与。其中，斯派柯国际有限公司获配32,000,000股，大湾区 共同家园投资有限公司旗下GIGA Industries Limited及Poly Platinum Enterprises Limited分别获配 11,086,000股和6,651,000股。上述基石投资者合计获配49,737,000股，占全球发售总股份的40.78%。 西藏智汇矿业股份有限公司（以下简称"智汇矿业"，股票代码：2546）今日公布其全球发售结果。根据 公告，公司最终确定发行价为每股4.51港元，该价格未披露价格区间，为固定定价。本次全球发售的股 份总数为121,952,000股H股，其中香港公开发售股份12,196,000股，国际配售股份109,756,000股，未设 置超额配售权。按最终发行价计算，本次发行募集资金总额约5.5亿港元，扣除估计应支付的上市开支 5490万港元后，募集资金净额约5.0亿港元。 认购情况方面，香港公开发售部分共收到177,542份有效申请，认购倍数高达5,248.15倍；国际配售部分 认购倍数为2.68倍，涉及164名承配人。由于香港公开发售超额认购未触发回拨机 ...

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不會就本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定者外，本公告所用詞彙與安徽金岩高嶺土新材料股份有限公司（「本公司」）所 刊發日期為2025年11月25日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告不會直接或間接於或向美國（包括美國的領土及屬地、美國任何州以及哥倫比亞特區）發 佈、刊發或派發。本公告並不構成亦不屬於在香港、美國或於任何其他司法權區購買或認購證 券的任何要約或招攬的一部分。發售股份並無亦不會根據《1933年美國證券法》（經不時修訂） （「美國證券法」）登記。發售股份不得在美國境內提呈發售、出售、質押或以其他方式轉讓，惟 根據美國證券法的登記規定獲豁免者或毋須遵守有關規定的交易除外。不會在美國公開發售發 售股份。發售股份根據美國證券法S規例以離岸交易方式在美國境外提呈發售及出售。 就全球發售而言，國元融資（香港）有限公司及民銀資本有限公司擔任聯席保薦人；國元證券 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何 責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。本公告並非招股章 程。潛在投資者於決定是否投資於由此提呈發售的H股前，應細閱上海寶濟藥業股份有限公司 （「本公司」）日期為2025年12月2日的招股章程（「招股章程」）以了解下文所述有關全球發售的詳 細資料。投資者應僅依賴招股章程所載資料作出有關發售股份的任何投資決定。 除本公告另有界定者外，本公告所用詞彙與招股章程所界定者具備相同涵義。 發售股份的潛在投資者務請注意，倘於上市日期（目前預期為2025年12月10日（星期三））上午 八時正（香港時間）之前任何時間發生招股章程「包銷 － 包銷安排及開支 － 香港公開發售 － 終 止理由」一節所載任何事件，整體協調人（為其本身及代表香港包銷商）有權立即終止其根據香 港包銷協議須承擔的責任。 1 Shanghai Bao Pharmaceuti ...

Group 1 - The company, Hebei Haiwei Electronic Materials Technology Co., Ltd., announced the results of its global offering, with a final issue price set at HKD 14.28 per share and a total of 35,456,000 H-shares offered, including an additional 4,624,600 shares due to the exercise of the over-allotment option [1] - The total proceeds from the global offering are approximately HKD 510 million, with a net amount of about HKD 450 million after estimated listing expenses [1] - The Hong Kong public offering received 165,803 valid applications, resulting in an oversubscription of 5,426.27 times, with 3,545,600 shares allocated, representing 10% of the total shares offered [1] Group 2 - The international placement had a subscription multiple of 6.11 times (before considering the over-allotment option), with 31,910,400 shares allocated, accounting for 90% of the total offering [1] - The cornerstone investor, Huixinglihai, was allocated 15,129,000 shares, which is 42.67% of the total shares offered, with a lock-up period of 6 months post-listing, ending on May 27, 2026 [1] - The exclusive sponsor for this issuance is China International Capital Corporation Hong Kong Securities Limited, with other coordinating and joint global coordinators including CITIC Securities and Bank of China International [2]

Core Viewpoint - Haiwei Co., Ltd. has successfully completed its global offering, raising approximately HKD 452 million through the issuance of 35.256 million shares at a price of HKD 14.28 per share [1] Summary by Category Offering Details - The global offering consisted of 35.256 million shares, with 10% allocated to the Hong Kong public offering and 90% to international offering [1] - The expected trading start date for H-shares on the Hong Kong Stock Exchange is November 28, 2025, at 9:00 AM Hong Kong time [1] Subscription Demand - The Hong Kong public offering was oversubscribed by 5,426.27 times, indicating strong local investor interest [1] - The international offering was oversubscribed by 6.11 times, reflecting robust demand from international investors [1]

Core Viewpoint - The company, Haiwei Co., Ltd. (09609.HK), announced a global offering of 35,456,000 H-shares at a price of HKD 14.28 per share, with net proceeds amounting to HKD 452 million [1] Summary by Category Offering Details - The Hong Kong public offering accounts for 10% of the total global offering, with a subscription rate of 5,426.27 times [1] - The international offering constitutes 90% of the total global offering, with a subscription rate of 6.11 times [1] Trading Information - If the global offering becomes unconditional by November 28, 2025, trading of the H-shares is expected to commence on the Hong Kong Stock Exchange at 9:00 AM (Hong Kong time) on the same day [1] - H-shares will be traded in lots of 200 shares, with the stock code being 9609 [1]